Pure Global AI
NCT06412185Not yet recruiting

Single Dose Escalation Study of CM383 in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single Dose Escalation of CM383 in Male Healthy Subjects
Keymed Biosciences Co.LtdPhase 1ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Alzheimer Disease
Drug/Device/Intervention
CM383
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Keymed Biosciences Co.Ltd
Timeline & enrollment
Phase
Phase 1
Start date
Jun 30, 2024
End date
Jun 30, 2025
Enrollment
44 participants
Primary outcome

Adverse events

Summary

This study is a single center, randomized, double-blind, placebo-controlled Phase I clinical
 study in a single dose escalation to evaluate its safety, tolerability, pharmacokinetics,
 pharmacodynamics, and immunogenicity of CM383 in male healthy subjects.

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06412185
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06412185 through Pure Global AI's free database. This Phase 1 trial is sponsored by Keymed Biosciences Co.Ltd and is currently Not yet recruiting. The study focuses on Alzheimer Disease. Target enrollment is 44 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.